Document is current
Any future updates will be listed below
-
Authors
Galli, Edoardo https://orcid.org/0000-0002-9760-2643
Hartmann, Felix J.
Schreiner, Bettina
Ingelfinger, Florian
Arvaniti, Eirini
Diebold, Martin https://orcid.org/0000-0001-9636-6936
Mrdjen, Dunja https://orcid.org/0000-0001-9269-2806
van der Meer, Franziska
Krieg, Carsten
Nimer, Faiez Al
Sanderson, Nicholas
Stadelmann, Christine
Khademi, Mohsen
Piehl, Fredrik https://orcid.org/0000-0001-8329-5219
Claassen, Manfred
Derfuss, Tobias
Olsson, Tomas
Becher, Burkhard https://orcid.org/0000-0002-1541-7867
- License Information
-
More Information
Article History
Received: 31 January 2019
Accepted: 11 June 2019
First Online: 22 July 2019
Competing interests
: T.O. has received unrestricted MS research grants, in addition to lecture and or advisory board honoraria, from Biogen, Novartis, Sanofi, Merck and Roche. M.D. received speaker honoraria from Biogen Switzerland, which were used exclusively for research purposes. F.P. has received research grants from Biogen, Genzyme, Merck and Novartis, and fees for serving as Data Monitoring Committee Chair in clinical trials with Parexel. T.D. received financial compensation for participation in advisory boards, steering committees and data safety monitoring boards, and for consultation for Novartis Pharmaceuticals, Merck, Biogen, Celgene, GeNeuro, Mitsubishi Tanabe Pharma, MedDay, Roche and Sanofi Genzyme. T.D. also received research support from Novartis, Biogen, the National Swiss Science Foundation, the European Union and the Swiss MS Society.
